Interactions among low dose of methotrexate and drugs used in the treatment of rheumatoid arthritis

Advances in Pharmacological Sciences

Volumn 2013, Issue , 2013, Pages

  Patanè, Marinella ^a,b   Ciriaco, Miriam ^a,b   Chimirri, Serafina ^a,b   Ursini, Francesco ^a   Naty, Saverio ^a   Grembiale, Rosa Daniela ^a   Gallelli, Luca ^a,b   De Sarro, Giovambattista ^a,b   Russo, Emilio ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Policlinico Mater Domini   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CELECOXIB; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DICLOFENAC; ETANERCEPT; ETORICOXIB; GOLIMUMAB; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; LUMIRACOXIB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BONE MARROW SUPPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; FEVER; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; INFECTION; INJECTION SITE PAIN; LOADING DRUG DOSE; LOW DRUG DOSE; MYALGIA; MYOSITIS; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SIDE EFFECT; VERTIGO;

EID: 84878628722     PISSN: 16876334     EISSN: 16876342     Source Type: Journal    
DOI: 10.1155/2013/313858     Document Type: Review

References (85)

1. Tambar S., Ruderman E. M., Current management of rheumatoid arthritis. Managed Care Interface 2007 20 7 18 24 (Pubitemid 47281760)
2. De Fazio S., Gallelli L., Gareri P., Mazzotta D., Rende P. A., De Sarro G., Pharmacological properties of nonsteroideal anti-inflammatory drugs: a review. Current Topics in Pharmacology 2009 13 1 75 83 2-s2.0-79551666063
3. Gallelli L., Galasso O., Urzino A., Characteristics and clinical implications of the pharmacokinetic profile of ibuprofen in patients with knee osteoarthritis. Clinical Drug Investigation 2012 32 827 833
4. Oliva F., Gallelli L., Ibuprofen pharmacology and its implications for musculoskeletal disorders. Functional Neurology 2010 25 3, supplement 1 1 19 2-s2.0-79955938801
5. Gallelli L., Colosimo M., Pirritano D., Ferraro M., De Fazio S., Marigliano N. M., De Sarro G., Retrospective evaluation of adverse drug reactions induced by nonsteroidal anti-inflammatory drugs. Clinical Drug Investigation 2007 27 2 115 122 2-s2.0-33846414380 10.2165/00044011-200727020- 00004 (Pubitemid 46143286)
6. Bijlsma J. W., Disease control with glucocorticoid therapy in rheumatoid arthritis. Rheumatology 2012 51 supplement 4 9 13
7. Boers M., Prednisone for rheumatoid arthritis: the detriment of the doubt. Nederlands Tijdschrift voor Geneeskunde 2012 155 32 A5069
8. Clarke L., Kirwan J., Efficacy, safety and mechanism of action of modified-release prednisone in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 2012 4 3 159 166
9. Haugeberg G., Strand A., Kvien T. K., Kirwan J. R., Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Archives of Internal Medicine 2005 165 11 1293 1297 2-s2.0-21744453971 10.1001/archinte.165.11.1293 (Pubitemid 40989595)
10. Makrygiannakis D., Revu S., Engstrom M., Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis. Arthritis Research & Therapy 2012 14 1 R20
11. McKeown E., Bykerk V. P., De Leon F., Bonner A., Thorne C., Hitchon C. A., Boire G., Haraoui B., Ferland D. S., Keystone E. C., Pope J. E., CATCH Investigators. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology 2012 51 9 1662 1669
12. Montecucco C., Todoerti M., Sakellariou G., Scirè C. A., Caporali R., Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Research & Therapy 2012 14 3 R112
13. O'Dell J. R., Therapeutic strategies for rheumatoid arthritis. The New England Journal of Medicine 2004 350 25 2591 2630 2-s2.0-20244372077 10.1056/NEJMra040226 (Pubitemid 38758546)
14. Quax R. A., Koper J. W., de Jong P. H., In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis. Arthritis Research & Therapy 2012 14 4 R195
15. Scott D. L., Pugner K., Kaarela K., Doyle D. V., Woolf A., Holmes J., Hieke K., The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000 39 2 122 132 2-s2.0-0034104307 (Pubitemid 30139344)
16. Baschant U., Lane N. E., Tuckermann J., The multiple facets of glucocorticoid action in rheumatoid arthritis. Nature Reviews Rheumatology 2012 8 11 645 655
17. Lee S.-G., Park Y.-E., Park S.-H., Increased frequency of osteoporosis and BMD below the expected range for age among South Korean women with rheumatoid arthritis. International Journal of Rheumatic Diseases 2012 15 3 289 296 10.1111/j.1756-185X.2012.01729.x
18. Curtis J. R., Lanas A., John A., Johnson D. A., Schulman K. L., Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care & Research 2012 64 12 1819 1828 10.1002/acr.21764
19. Zeidler J., Zeidler H., Graf von der Schulenburg J. M., Therapy of rheumatoid arthritis with methotrexate: claims data analysis of treatment patterns. Zeitschrift für Rheumatologie 2012 71 10 900 907
20. Kruger K., Wollenhaupt J., Albrecht K., guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm. Zeitschrift für Rheumatologie 2012 71 7 592 603
21. Protogerou A. D., Zampeli E., Sfikakis P. P., Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. Annals of Internal Medicine 2012 157 4 299 300
22. Agarwal S. K., Biologic agents in rheumatoid arthritis: an update for managed care professionals. Journal of Managed Care Pharmacy 2011 179 supplement B S14 S18
23. Saag K. G., Gim G. T., Patkar N. M., Anuntiyo J., Finney C., Curtis J. R., Paulus H. E., Mudano A., Pisu M., Elkins-Melton M., Outman R., Allison J. J., Almazor M. S., Bridges S. L., Chatham W. W., Hochberg M., Maclean C., Mikuls T., Moreland L. W., O'Dell J., Turkiewicz A. M., Furst D. E., American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care and Research 2008 59 6 762 784 2-s2.0-45349090538 10.1002/art.23721 (Pubitemid 351847559)
24. Gallelli L., Ferreri G., Colosimo M., Pirritano D., Guadagnino L., Pelaia G., Maselli R., De Sarro G. B., Adverse drug reactions to antibiotics observed in two pulmonology divisions of Catanzaro, Italy: a six-year retrospective study. Pharmacological Research 2002 46 5 395 400 2-s2.0-0036435711 10.1016/S1043661802002104 (Pubitemid 35352201)
25. Gallelli L., Ferreri G., Colosimo M., Pirritano D., Flocco M. A., Pelaia G., Maselli R., De Sarro G. B., Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy. Pharmacological Research 2003 47 6 493 499 2-s2.0-0037624839 10.1016/S1043-6618(03)00003-3 (Pubitemid 36542928)
26. Gallelli L., Guadagnino V., Caroleo B., Marigliano N., De Sarro G. B., Izzi A., Bilateral skin ulceration after injection of pegylated interferon- α -2b in a patient with chronic hepatitis C. Clinical Drug Investigation 2003 23 9 615 619 2-s2.0-0141724908 10.2165/00044011-200323090-00009 (Pubitemid 37115079)
27. Gallelli L., Nardi M., Prantera T., Barbera S., Raffaele M., Arminio D., Pirritano D., Colosimo M., Maselli R., Pelaia G., De Gregorio P., De Sarro G. B., Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer. Pharmacological Research 2004 49 3 259 263 2-s2.0-0346059435 10.1016/j.phrs.2003.10.001 (Pubitemid 38064337)
28. Gallelli L., Guadagnino V., Caroleo B., Marigliano N., De Sarro G., Cutaneous ulceration induced by interferon alfa. Annals of Pharmacotherapy 2004 38 1 173 174 2-s2.0-0345731429 (Pubitemid 38018030)
29. Gallelli L., Del Negro S., Naty S., Colosimo M., Maselli R., De Sarro G., Levofloxacin-induced taste perversion, blurred vision and dyspnoea in a young woman. Clinical Drug Investigation 2004 24 8 487 489 2-s2.0-4344573415 10.2165/00044011-200424080-00007 (Pubitemid 39128015)
30. Gareri P., Gallelli L., Ferreri Ibbadu G., Lacava R., Russo E., De Sarro G., Melaena following use of the cholinesterase inhibitor rivastigmine. Clinical Drug Investigation 2005 25 3 215 217 2-s2.0-16244401933 10.2165/00044011- 200525030-00008 (Pubitemid 40460648)
31. Gallelli L., Ferraro M., Mauro G. F., De Sarro G., Generalised dermatitis induced by pegylated interferon- α -2b in a patient infected with genotype-1 hepatitis C virus: presentation of a case. Clinical Drug Investigation 2005 25 4 281 284 2-s2.0-17844377964 10.2165/00044011-200525040- 00009 (Pubitemid 40593617)
32. Gallelli L., Ferraro M., Mauro G. F., De Fazio S., De Sarro G., Nimesulide-induced hepatotoxicity in a previously healthy woman. Clinical Drug Investigation 2005 25 6 421 424 2-s2.0-22544466408 10.2165/00044011-200525060- 00008 (Pubitemid 41019990)
33. Gallelli L., Gallelli A., Vero G., Roccia F., Pelaia G., De Sarro G., Maselli R., Acute renal failure probably induced by prulifloxacin in an elderly woman: a first case report. Clinical Drug Investigation 2006 26 1 49 53 2-s2.0-30744437424 10.2165/00044011-200626010-00007 (Pubitemid 43098409)
34. Gallelli L., De Fazio S., Corace E., De Sarro C., Garcia C. S., De Fazio P., Generalised urticaria in a young woman treated with clomipramine and after ingestion of codfish: a case report. Pharmacopsychiatry 2006 39 4 154 156 2-s2.0-33746883527 10.1055/s-2006-946707 (Pubitemid 44199185)
35. Siniscalchi A., Gallelli L., De Sarro G., Combined topiramate and declorazepam therapy in a patient affected by essential tremor. Parkinsonism and Related Disorders 2007 13 2 129 130 2-s2.0-33847371987 10.1016/j.parkreldis. 2006.05.032 (Pubitemid 46343616)
36. Gareri P., De Fazio P., Cotroneo A., Lacava R., Gallelli L., De Fazio S., De Sarro G., Anticholinergic drug-induced delirium in an elderly alzheimer's dementia patient. Archives of Gerontology and Geriatrics 2007 44 199 206 2-s2.0-33847240928 10.1016/j.archger.2007.01.027
37. Siniscalchi A., Gallelli L., De Fazio S., De Sarro G., Psychic disturbances associated with sodium valproate plus levetiracetam. Annals of Pharmacotherapy 2007 41 3 527 528 2-s2.0-34047192366 10.1345/aph.1H614 (Pubitemid 46536050)
38. Gareri P., De Fazio P., Gallelli L., De Fazio S., Davoli A., Seminara G., Cotroneo A., De Sarro G., Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation. Annals of Pharmacotherapy 2008 42 3 434 438 2-s2.0-41149084551 10.1345/aph.1K405 (Pubitemid 351429612)
39. Gallelli L., Staltari O., Palleria C., De Sarro G., Ferraro M., Hepatotoxicity induced by methimazole in a previously health patient. Current Drug Safety 2009 4 3 204 206 2-s2.0-73349105618 10.2174/157488609789006912
40. Siniscalchi A., Gallelli L., Calabrò G., Tolotta G. A., De Sarro G., Phenobarbital/lamotrigine coadministration-induced blood dyscrasia in a patient with epilepsy. Annals of Pharmacotherapy 2010 44 12 2031 2034 2-s2.0-78649955813 10.1345/aph.1P335
41. Di Mizio G., Gallelli L., Barbieri V., Loiacono D., Colosimo F., Rende P., Di Nunzio C., Ricci P., Capecitabine-induced, rapid decrease of renal function due to drug dispensing error in a hospital pharmacy. Journal of Clinical Pharmacology 2011 51 1 117 119 2-s2.0-78650816714 10.1177/ 0091270010365552
42. Scicchitano F., Giofrè C., Palleria C., Mazzitello C., Ciriaco M., Gallelli L., Paletta L., Marrazzo G., De Fazio S., Menniti M., Curia R., Arena Cm Chimirri S., Patanè M., Esporito S., Cilurzo F., Staltari O., Russo E., De Sarro G., Pharmacovigilance and drug safety 2011 in Calabria (Italy): adverse events analysis. Journal of Research in Medical Sciences 2012 17 9 872 875
43. Dalrymple J. M., Stamp L. K., O'Donnell J. L., Chapman P. T., Zhang M., Barclay M. L., Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism 2008 58 11 3299 3308 2-s2.0-55849140884 10.1002/art.24034
44. Seideman P., Beck O., Eksborg S., Wennberg M., The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. British Journal of Clinical Pharmacology 1993 35 4 409 412 2-s2.0-0027526252 (Pubitemid 23103382)
45. Segal R., Mozes E., Yaron M., Tartakovsky B., The effects of methotrexate on the production and activity of interleukin-1. Arthritis and Rheumatism 1989 32 4 370 377 2-s2.0-0024554111 (Pubitemid 19118661)
46. Segal R., Yaron M., Tartakovsky B., Methotrexate: mechanism of action in rheumatoid arthritis. Seminars in Arthritis and Rheumatism 1990 20 3 190 200 2-s2.0-0025553522 10.1016/0049-0172(90)90060-S
47. Tan K. W., Tay Y. K., A case of acute methotrexate toxicity. Annals of the Academy of Medicine Singapore 2011 40 2 97 99 2-s2.0-79952581858
48. Schwartz J. I., Agrawal N. G. B., Wong P. H., Miller J., Bachmann K., Marbury T., Hoelscher D., Cavanaugh P. F., Gottesdiener K., Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. Journal of Clinical Pharmacology 2009 49 10 1202 1209 2-s2.0-70349515537 10.1177/0091270009338939
49. Honjo H., Uwai Y., Iwamoto K., Inhibitory effect of selective cyclooxygenase-2 inhibitor etoricoxib on human organic anion transporter 3 (hOAT3). Drug Metabolism Letters 2011 5 2 140 137
50. Karim A., Tolbert D. S., Hunt T. L., Hubbard R. C., Harper K. M., Geis G. S., Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. Journal of Rheumatology 1999 26 12 2539 2543 2-s2.0-0032755693
51. Hartmann S. N., Rordorf C. M., Milosavljev S., Branson J. M., Chales G. H., Juvin R. R., Lafforgue P., Le Parc J. M., Tavernier C. G., Meyer O. C., Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients. Annals of Pharmacotherapy 2004 38 10 1582 1587 2-s2.0-10444252228 10.1345/aph.1E044 (Pubitemid 39297750)
52. Palleria C., Di Paolo A., Giofrè C., Caglioti C., Leuzzi G., Siniscalchi A., De Sarro G., Gallelli L., Pharmacokinetic drug-drug interaction and their implication in clinical management. Journal of Research in Medical Sciences 2013
53. Colebatch A. N., Marks J. L., van der Heijde D. M., Edwards C. J., Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. Journal of Rheumatology. Supplement 2012 90 62 73
54. Arava (Leflunomide),. Sanofi-Aventis. UK Summary of product characteristics, September 2009
55. EMEA, EMEA public statement on leflunomide (Arava)-severe and serious hepatic reactions. London, UK, March 2001, http://www.emea.europa.eu/docs/en-GB/ document-library/Public-statement/2009/12/WC500018389.pdf
56. Hill R. L., Topliss D. J., Purcell P. M., Pancytopenia associated with leflunomide and methotrexate. Annals of Pharmacotherapy 2003 37 1 149 2-s2.0-0037224358
57. McEwen J., Purcell P. M., Hill R. L., Calcino L. J., Riley C. G., The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. Pharmacoepidemiology and Drug Safety 2007 16 1 65 73 2-s2.0-33846531248 10.1002/pds.1236 (Pubitemid 46164977)
58. Chan J., Sanders D. C., Du L., Pillans P. I., Leflunomide-associated pancytopenia with or without methotrexate. Annals of Pharmacotherapy 2004 38 7-8 1206 1211 2-s2.0-3042550512 10.1345/aph.1E012 (Pubitemid 38802163)
59. Londono J., Santos A. M., Santos P. I., Cubidez M. F., Guzman C., Valle-Oñate R., Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment. Revista Brasileira de Reumatologia 2012 52 6 837 845
60. Lee S. W., Park H. J., Kim B. K., Han K. H., Lee S. K., Kim S. U., Park Y. B., Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Research & Therapy 2012 14 5 R232
61. Katchamart W., Trudeau J., Phumethum V., Bombardier C., Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases 2009 68 7 1105 1112 2-s2.0-67549142546 10.1136/ard.2008.099861
62. Elsby R., Fox L., Stresser D., Layton M., Butters C., Sharma P., Smith V., Surry D., In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. European Journal of Pharmaceutical Sciences 2011 43 1-2 41 49 2-s2.0-79955691418 10.1016/j.ejps.2011.03.006
63. Gerards A. H., Landewé R. B. M., Prins A. P. A., Bruijn G. A. W., Thè H. S. G., Laan R. F. J. M., Dijkmans B. A. C., Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Annals of the Rheumatic Diseases 2003 62 4 291 296 2-s2.0-0037377961 10.1136/ard.62.4.291 (Pubitemid 36363432)
64. Sarzi-Puttini P., D'Ingianna E., Fumagalli M., Scarpellini M., Fiorini T., Chérié-Lignière E. L., Panni B., Fiorentini F., Corbelli V., Beyene N. B., Mastaglio C., Severi C., Locati M., Cazzola M., Menozzi G., Monti G., Saccardo F., Alfieri G., Atzeni F., An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatology International 2005 25 1 15 22 2-s2.0-21244483439
65. Fuksa L., Brcakova E., Kolouchova G., Hirsova P., Hroch M., Cermanova J., Staud F., Micuda S., Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats. Toxicology 2010 267 1-3 165 171 2-s2.0-71849102008 10.1016/j.tox.2009.11.010
66. Wolff J. E. A., Hauch H., Kühl J., Egeler R. M., Jürgens H., Dexamethasone increases hepatotoxicity of MTX in children with brain tumors. Anticancer Research 1998 18 4B 2895 2899 2-s2.0-0031844724 (Pubitemid 28388859)
67. Malysheva O. A., Wahle M., Wagner U., Pierer M., Arnold S., Häntzschel H., Baerwald C. G. O., Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. Journal of Rheumatology 2008 35 6 979 985 2-s2.0-44949249066 (Pubitemid 351813140)
68. Weinblatt M. E., Kremer J. M., Coblyn J. S., Maier A. L., Helfgott S. M., Morrell M., Byrne V. M., Kaymakcian M. V., Strand V., Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis & Rheumatism 1999 42 1322 1328 (Pubitemid 30265588)
69. Bird P., Griffiths H., Tymms K., The SMILE study-safety of methotrexate in combination with leflunomide in rheumatoid arthritis. The Journal of Rheumatology 2013 40 3 228 235 10.3899/jrheum.120922
70. Callen J. P., Complications and adverse reactions in the use of newer biologic agents. Seminars in Cutaneous Medicine and Surgery 2007 26 1 6 14 2-s2.0-33847389242 10.1016/j.sder.2006.12.002 (Pubitemid 46349778)
71. Luong B. T., Chong B. S., Lowder D. M., Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab. Annals of Pharmacotherapy 2000 34 6 743 760 2-s2.0-0034045894 (Pubitemid 30395775)
72. Zhou H., Mayer P. R., Wajdula J., Fatenejad S., Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. Journal of Clinical Pharmacology 2004 44 11 1235 1243 2-s2.0-6344284247 10.1177/0091270004268049 (Pubitemid 39391482)
73. Weisman M. H., Moreland L. W., Furst D. E., Weinblatt M. E., Keystone E. C., Paulus H. E., Teoh L. S., Velagapudi R. B., Noertersheuser P. A., Granneman G. R., Fischkoff S. A., Chartash E. K., Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clinical Therapeutics 2003 25 6 1700 1721 2-s2.0-0038721588 10.1016/S0149-2918(03)80164-9 (Pubitemid 36801943)
74. RoActemra (Tocilizumab),. Roche Registration Ltd. Summary of product characteristics, January 2009
75. Cimzia (Certolizumab pegol),. UCB Inc. US Prescribing information, December 2008
76. Simponi (Golimumab),. Centocor Ortho Biotech Inc. US Prescribing information, April 2009
77. Von Kempis J., Dudler J., Hasler P., Kyburz D., Tyndall A., Zufferey P., Villiger P. M., Use of abatacept in rheumatoid arthritis. Swiss Medical Weekly 2012 142
78. Dijkmans B., Gerards A., Cyclosporin in rheumatoid arthritis: monitoring for adverse effects and clinically significant drug interactions. BioDrugs 1998 10 6 437 445 2-s2.0-0032425055 10.2165/00063030-199810060-00002 (Pubitemid 29013720)
79. Baraldo M., Ferraccioli G., Pea F., Gremese E., Furlanut M., Cyclosporine a pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy. Pharmacological Research 1999 40 6 483 486 2-s2.0-0032763097 10.1006/phrs.1999.0539
80. Velagapudi R. B., Noertersheuser P. A., Awni W. M., Fischkoff S. A., Kupper H., Granneman R. G., van de Putte L. B. A., Keystone E. C., Effect of methotrexate coadministration on the pharmacokinetics of adalimumab (Humira, Abbott) following a single intravenous injection. Arthritis & Rheumatism 2003 48 S141
81. Humira (Adalimumab),. Abbott Laboratories. US Prescribing information, March 2009
82. Davies B., Shaw T., Rituximab pharmacokinetic characteristics are not influenced by combination with methotrexate or cyclophosphamide. Annals of the Rheumatic Diseases 2004 63 FRI0128
83. Singh J. A., Wells G. A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J. K., Filippini G., Skoetz N., Francis D., Lopes L. C., Guyatt G. H., Schmitt J., La Mantia L., Weberschock T., Roos J. F., Siebert H., Hershan S., Lunn M. P., Tugwell P., Buchbinder R., Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane Database of Systematic Reviews 2011 2 CD008794 2-s2.0-79953018875
84. Thompson A. E., Bashook P. G., Rheumatologists' recommended patient information when prescribing methotrexate for rheumatoid arthritis. Clinical and Experimental Rheumatology 2010 28 4 539 545 2-s2.0-79952061556
85. van Roon E. N., van den Bemt P. M. L. A., Jansen T. L. T. A., Houtman N. M., van de Laar M. A. F. J., Brouwers J. R. B. J., An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. Clinical Therapeutics 2009 31 8 1737 1746 2-s2.0-72149108430 10.1016/j.clinthera.2009.08.009